2018 Irregular Heartbeat Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Irregular Heartbeat Market
Irregular Heartbeat refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Irregular Heartbeat condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Irregular Heartbeat pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Irregular Heartbeat pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Irregular Heartbeat pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Irregular Heartbeat pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Irregular Heartbeat pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Irregular Heartbeat pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 IRREGULAR HEARTBEAT PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Irregular Heartbeat Pipeline Snapshot
2.3 Irregular Heartbeat Pipeline by Phase
2.4 Irregular Heartbeat Pipeline by Company
2.5 Irregular Heartbeat Pipeline by Mechanism of Action
3 IRREGULAR HEARTBEAT- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc
4 IRREGULAR HEARTBEAT R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN IRREGULAR HEARTBEAT PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 IRREGULAR HEARTBEAT PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Irregular Heartbeat Pipeline Snapshot
2.3 Irregular Heartbeat Pipeline by Phase
2.4 Irregular Heartbeat Pipeline by Company
2.5 Irregular Heartbeat Pipeline by Mechanism of Action
3 IRREGULAR HEARTBEAT- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc
4 IRREGULAR HEARTBEAT R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN IRREGULAR HEARTBEAT PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Irregular Heartbeat Pipeline by Phase, H2- 2018
Figure 2: Irregular Heartbeat Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Irregular Heartbeat Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Irregular Heartbeat Pipeline by Phase, H2- 2018
Figure 2: Irregular Heartbeat Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Irregular Heartbeat Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Irregular Heartbeat Pipeline by Phase, H2- 2018
Irregular Heartbeat Pipeline by Companies, H2- 2018
Irregular Heartbeat Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Irregular Heartbeat Pipeline Drugs, H2- 2018
Irregular Heartbeat Pipeline by Phase, H2- 2018
Irregular Heartbeat Pipeline by Companies, H2- 2018
Irregular Heartbeat Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Irregular Heartbeat Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Irregular Heartbeat Pipeline Drugs, H2- 2018
